Brii Bio backs in­fec­tious dis­ease start­up while ink­ing deal for its lead TB drug, dou­bling down on an­tibi­otics

Al­most two years af­ter leav­ing GSK to launch Brii Bio with a whop­ping $260 mil­lion in fund­ing, Zhi Hong is see­ing the trans-Pa­cif­ic in­fec­tious dis­ease spe­cial­ist he set out to build take shape.

“Our pipeline is com­ing to­geth­er,” he told End­points News, with 12 part­nered as­sets plus some in­ter­nal pro­grams.

As its lat­est part­ner, AN2 Ther­a­peu­tics, comes in­to the lime­light for the first time with a $12 mil­lion seed round, so is Brii’s plans in the an­tibi­otics space. Brii has ob­tained Chi­na rights to AN2’s an­tibac­te­r­i­al tar­get­ing my­cobac­teri­um tu­ber­cu­lo­sis for mul­ti-drug re­sis­tant TB, which it says is in the clin­i­cal stage.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.